+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID04838652

Phase 2 Study of Pembrolizumab with Chemotherapy for First-Relapsed or Refractory Classical Hodgkin Lymphoma in Adults Aged 18 to 65

Led by University of Cologne · Updated on 2024-08-23

29

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a treatment approach for people with first-relapsed or refractory classical Hodgkin lymphoma cHL. The trial aims to find an effective and well-tolerated regimen by adding the anti-PD-1 antibody pembrolizumab to established chemotherapy treatments. This combination may work together to create a powerful therapy with fewer side effects, potentially replacing the more harmful high-dose chemotherapy currently used. Participants will first receive a single intravenous dose of 200 mg pembrolizumab alone. This is followed by two cycles of pembrolizumab combined with ifosfamide, carboplatin, and etoposide P-ICE, with a PETCT scan to assess response. Based on the PET results, participants will either get two more cycles of P-ICE if the scan is negative or two to four cycles of pembrolizumab combined with dexamethasone, cytarabine, and cisplatin P-DHAP if the scan is positive. After this, all participants receive six additional cycles of pembrolizumab as consolidation therapy. If the disease is not in complete remission after at least four cycles, doctors may opt for high-dose chemotherapy or another standard treatment. During the trial, researchers will monitor participants responses using PETCT scans and assess safety and treatment effects. The primary outcome is the rate of complete metabolic response about three months after finishing pembrolizumab and chemotherapy. Participants will be closely followed to evaluate how well the combination treatment works and to track any side effects. The entire study will include adults aged 18 to 65 years with this lymphoma type.

CONDITIONS

Brief Title

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Research Team

M

Michael Fuchs

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here